Literature DB >> 12604337

Merlin suppresses the SRE-dependent transcription by inhibiting the activation of Ras-ERK pathway.

Jung Yeon Lim1, Hongtae Kim, Young Hoon Kim, Sae Woong Kim, Pil-Woo Huh, Kweon-Haeng Lee, Sin-Soo Jeun, Hyoung Kyun Rha, Joon-ki Kang.   

Abstract

The neurofibromatosis type 2 (NF2) gene encodes an intracellular membrane-associated protein called merlin or schwannomin, which is known to be a tumor suppressor. Numerous studies have suggested that merlin is involved in the regulation of cell growth and proliferation. Previously, merlin/schwannomin was reported to block Ras-induced cell proliferation and anchorage-independent cell growth. Also, the N-terminus of merlin was found to suppress cell proliferation, although it appears to be less effective than full-length merlin. However, the inhibitory mechanism of merlin is unknown. In this report, merlin is shown to be effective at suppressing serum/Ras-induced and Elk-mediated SRE dependent transactivation, and serum-induced ERK phosphorylation in NIH3T3 cells. In addition, merlin inhibited serum-induced Elk phosphorylation, a downstream effector of ERKs. Also, the N-terminal deficient merlin mutant could not block serum-induced and Elk-mediated SRE dependent transactivation, although the C-terminal deficient merlin mutant could. These results suggest that merlin inhibits SRE dependent transactivation by repressing serum-induced ERK phosphorylation and its downstream effector, Elk phosphorylation. Also, the N-terminus of merlin may be important for its inhibitory effect. Our results show that merlin acts as a negative regulator of the SRE signaling pathway via the Ras-ERKs pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12604337     DOI: 10.1016/s0006-291x(03)00124-4

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L.

Authors:  Rong Rong; Xiaoling Tang; David H Gutmann; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-14       Impact factor: 11.205

Review 2.  News on the genetics, epidemiology, medical care and translational research of Schwannomas.

Authors:  C O Hanemann; D G Evans
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

3.  Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice.

Authors:  Miki Nishio; Koichi Hamada; Kohichi Kawahara; Masato Sasaki; Fumihito Noguchi; Shuhei Chiba; Kensaku Mizuno; Satoshi O Suzuki; Youyi Dong; Masaaki Tokuda; Takumi Morikawa; Hiroki Hikasa; Jonathan Eggenschwiler; Norikazu Yabuta; Hiroshi Nojima; Kentaro Nakagawa; Yutaka Hata; Hiroshi Nishina; Koshi Mimori; Masaki Mori; Takehiko Sasaki; Tak W Mak; Toru Nakano; Satoshi Itami; Akira Suzuki
Journal:  J Clin Invest       Date:  2012-11-12       Impact factor: 14.808

Review 4.  Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.

Authors:  Jaishri O Blakeley; Scott R Plotkin
Journal:  Neuro Oncol       Date:  2016-02-06       Impact factor: 12.300

5.  Contribution of persistent C-Jun N-terminal kinase activity to the survival of human vestibular schwannoma cells by suppression of accumulation of mitochondrial superoxides.

Authors:  Wei Ying Yue; J Jason Clark; Augusta Fernando; Frederick Domann; Marlan R Hansen
Journal:  Neuro Oncol       Date:  2011-06-22       Impact factor: 12.300

6.  A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.

Authors:  Fares Nigim; Shin-Ichi Esaki; Michael Hood; Nina Lelic; Marianne F James; Vijaya Ramesh; Anat Stemmer-Rachamimov; Daniel P Cahill; Priscilla K Brastianos; Samuel D Rabkin; Robert L Martuza; Hiroaki Wakimoto
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

7.  Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.

Authors:  Maurits de Vries; Inge Briaire-de Bruijn; Anne-Marie Cleton-Jansen; Martijn J A Malessy; Andel G L van der Mey; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2012-12-08       Impact factor: 4.064

8.  A genetic screen for dominant modifiers of a cyclin E hypomorphic mutation identifies novel regulators of S-phase entry in Drosophila.

Authors:  Anthony Brumby; Julie Secombe; Julie Horsfield; Michelle Coombe; Nancy Amin; Deborah Coates; Robert Saint; Helena Richardson
Journal:  Genetics       Date:  2004-09       Impact factor: 4.562

9.  The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.

Authors:  J Jason Clark; Matthew Provenzano; Henry R Diggelmann; Ningyong Xu; Skylar S Hansen; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2008-09       Impact factor: 2.311

Review 10.  Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator.

Authors:  Sarah Beltrami; Richard Kim; Jennifer Gordon
Journal:  Anticancer Res       Date:  2013-01       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.